Yes, sure. Thanks. I mean, it's good, right. We've had a total of, I think, 37 days of owning OTC. So – but rest assured, as you know, as Patrick, we are hard at work with the integration, and we're very happy with the – what we've seen so far. I mean, look, in the implied guidance, we separated guidance out for you. So you saw at the sort of midpoint of guidance, we expect $115 million, which as you would guess, shows decent growth from the $400 million that we initially expected. Look, in terms of – and in terms of the margin itself, I think we said on the previous call that BGC as a group, has margins in excess of – pretax margins in excess of 20%, whereas when you're buying a larger company like OTC, that has smaller margins to start with. And as you can see, you can work out the implied margin from our guidance. That's why we did that work for you. But that's immediately. We've done huge amounts of small transactions and we get the economies of scale. We're also very experienced at the larger transactions, such as GFI. And what I would expect is as I said before, whilst we don't think the OTC business will get up to the BGC margins in the short-term, you will definitely see a growth in those margins by the end of year one, beginning of year two. Maybe, John, you wanted to add something in terms of the business itself and the synergy.